Published in Hum Mol Genet on September 01, 2002
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood (2011) 2.47
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
Genetic disorders of the skeleton: a developmental approach. Am J Hum Genet (2003) 1.52
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol (2007) 1.15
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. J Bone Miner Metab (2010) 0.97
New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int (2010) 0.94
New roles of osteoblasts involved in osteoclast differentiation. World J Orthop (2012) 0.89
RANK ligand and the regulation of skeletal remodeling. J Clin Invest (2003) 0.88
Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK. Bone (2014) 0.84
Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. J Bone Miner Res (2013) 0.84
Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions. J Inherit Metab Dis (2007) 0.83
"Missing" inhibitors of calcification: general aspects and implications in renal failure. Pediatr Nephrol (2004) 0.82
TNFRSF11B computational development network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients. J Inflamm (Lond) (2010) 0.82
Deletion of 8q24 in an adult with mild dysmorphic features, developmental delay, and ketotic hypoglycemia. Am J Med Genet A (2010) 0.82
Ubiquitin-mediated signalling and Paget's disease of bone. BMC Biochem (2007) 0.80
Multicentric carpotarsal osteolysis syndrome is caused by only a few domain-specific mutations in MAFB, a negative regulator of RANKL-induced osteoclastogenesis. Am J Med Genet A (2014) 0.79
Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head. Am J Transl Res (2016) 0.78
Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS). PLoS One (2011) 0.78
Non-linear pattern formation in bone growth and architecture. Front Endocrinol (Lausanne) (2015) 0.78
The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders. J Clin Med (2014) 0.76
Hyperphosphatasia with massive osteoectasia: a 45-year follow-up. Skeletal Radiol (2006) 0.75
Sclerosing bone disorders: a lot of knowns but still some unknowns. Bonekey Rep (2012) 0.75
Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing. Croat Med J (2015) 0.75
Auricular ossification: A newly recognized feature of osteoprotegerin-deficiency juvenile Paget disease. Am J Med Genet A (2016) 0.75
Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway. Int J Clin Exp Pathol (2015) 0.75
Intermediate Type of Juvenile Paget's Disease: A Rare Case in Indian Population. Contemp Clin Dent (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (2008) 5.14
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Validation of zebrafish (Danio rerio) reference genes for quantitative real-time RT-PCR normalization. Acta Biochim Biophys Sin (Shanghai) (2007) 2.47
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr (2011) 2.44
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Low levels of genetic divergence across geographically and linguistically diverse populations from India. PLoS Genet (2006) 2.26
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet (2004) 2.04
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm (2010) 1.87
The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr (2007) 1.83
Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone (2007) 1.73
Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab (2010) 1.68
Community detection of long QT syndrome with a clinical registry: an alternative to ECG screening programs? Heart Rhythm (2012) 1.67
Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res (2002) 1.66
Decreased bone density in men on methadone maintenance therapy. Addiction (2010) 1.63
Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone (2012) 1.62
IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood (2007) 1.59
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res (2011) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum (2010) 1.52
Comprehensive mutation analysis for congenital muscular dystrophy: a clinical PCR-based enrichment and next-generation sequencing panel. PLoS One (2013) 1.51
The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone (2011) 1.50
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood (2009) 1.50
Association of fat-free mass and training status with left ventricular size and mass in endurance-trained athletes. J Am Coll Cardiol (2004) 1.48
Defining vitamin D deficiency. N Z Med J (2007) 1.45
Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res (2010) 1.45
Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand? N Z Med J (2012) 1.42
CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab (2007) 1.42
The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. N Z Med J (2007) 1.40
Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res (2011) 1.39
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res (2010) 1.37
Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum (2008) 1.36
Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol (2011) 1.35
In vitro and in vivo effects of adiponectin on bone. Endocrinology (2009) 1.35
Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. Heart Rhythm (2008) 1.33
Chemical discovery and global gene expression analysis in zebrafish. Nat Biotechnol (2003) 1.33
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem (2004) 1.31
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab (2005) 1.30
Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther (2005) 1.29
Mutations in the BRWD3 gene cause X-linked mental retardation associated with macrocephaly. Am J Hum Genet (2007) 1.26
Modulation of osteoclastogenesis by fatty acids. Endocrinology (2008) 1.25
Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone (2005) 1.25
beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res (2004) 1.25
Pathogenesis and management of Paget's disease of bone. Lancet (2008) 1.21
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2015) 1.18
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet (2013) 1.17
Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res (2003) 1.17
Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood (2006) 1.17
Vitamin D insufficiency and health outcomes over 5 y in older women. Am J Clin Nutr (2009) 1.17
Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. Blood (2007) 1.17
Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder. Brain (2013) 1.17
Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab (2004) 1.16
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest (2005) 1.16
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res (2007) 1.15
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab (2008) 1.14
Delta subunit susceptibility variants E177A and R220H associated with complex epilepsy alter channel gating and surface expression of alpha4beta2delta GABAA receptors. J Neurosci (2006) 1.14
Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clin Endocrinol (Oxf) (2007) 1.12
Calcium supplements increase risk of myocardial infarction. J Bone Miner Res (2015) 1.11
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther (2009) 1.11
Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications. Genet Med (2009) 1.10
Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood (2004) 1.09